This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies (DEMENSTIM)

This study is currently recruiting participants.
See Contacts and Locations
Verified December 2016 by University Hospital, Rouen
Sponsor:
Information provided by (Responsible Party):
University Hospital, Rouen
ClinicalTrials.gov Identifier:
NCT01340001
First received: April 5, 2011
Last updated: December 6, 2016
Last verified: December 2016
April 5, 2011
December 6, 2016
October 2012
October 2017   (Final data collection date for primary outcome measure)
free recalls of the FCSRT [ Time Frame: between the assessments (Month 7) and (Month 10) ]
The primary endpoint of the study is the difference in the sum of the three free recalls of the FCSRT between the assessments (M7) and (M10), i.e. the comparison of the performances with and without NBM electrical stimulation.
Same as current
Complete list of historical versions of study NCT01340001 on ClinicalTrials.gov Archive Site
performances on different tests [ Time Frame: different tests recorded at Month 7 and Month 10 ]
Comparison will be made between the performances on different tests recorded at M7 and M10, to evaluate the effect of bilateral electrical stimulation of the NBM on cognitivo-behavioral disorders.
Same as current
Not Provided
Not Provided
 
Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies
Effects of Nucleus Basalis of Meynert Area Electrical Stimulation on Cognitive Behavioral Disorders in Dementia With Lewy Bodies : A Pilot Phase 1 Study

Deep brain stimulation has been developed as a substitute for the classical lesioning methods previously used in stereotactic and functional neurosurgery. Recent, anecdotal cases reports suggested that electrical stimulation of the cholinergic output of the Nucleus Basalis of Meynert (NBM) may improve cognitive performances, especially the memory tasks.

The present study aims to assess the effect of bilateral electrical stimulation of the NBM on the mnesic performance [assessed by the sum of the three free recalls of the Free and Cued Selective Recall Reminding Test (FCSRT)] in patients diagnosed with probable, moderate, Dementia with Lewy Bodies.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Dementia With Lewy Bodies
Procedure: Electrical stimulation of the nucleus basalis of Meynert
Differents parameters will be assessed.
  • Sham Comparator: Sham Electrical stimulation of the nucleus basalis of Meynert
    Deep brain stimulation
    Intervention: Procedure: Electrical stimulation of the nucleus basalis of Meynert
  • Experimental: Electrical stimulation of the nucleus basalis of Meynert
    Deep brain stimulation
    Intervention: Procedure: Electrical stimulation of the nucleus basalis of Meynert
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
6
October 2017
October 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of probable Lewy-body dementia according to the internationally accepted consensus criteria (McKeith, 2005)
  • Outpatients, male or female, aged between 18 to 75 years
  • Moderate dementia defined by a mini-mental state examination (MMSE) score between 16 and 26
  • Stable dose of cholinesterase inhibitors (maximal dose tolerated) for a minimum of 1 months
  • Patients receiving antiparkinsonian treatment unmodified for 3 months, if treated
  • French as native language
  • Written informed consent of the patient
  • Written informed consent of the caregiver

Exclusion Criteria:

  • Other causes of dementia (Alzheimer dementia, vascular dementia, dementia associated with Parkinson's disease)
  • Other causes of extrapyramidal symptoms (Parkinson's disease)
  • Patients with a history of severe psychiatric disorders, such as psychosis. Earlier episodes of depression and/or anxiety without hospitalization are not exclusion criteria
  • Contraindications for MR imaging (claustrophobia, metallic foreign bodies, pacemakers, etc)
  • MRI evidence of cerebral microbleeds
  • Surgical contraindications: especially, hemostatic disorders, severe cortical atrophy
  • Patients receiving treatments that may interfere with the cholinergic system: anticholinergics, cholinomimetics.
  • Patients receiving neuroleptics
  • Patients with a history of alcohol or drug abuse
  • Pre-existing structural brain abnormalities (such as tumor, infarction, or intracranial hematoma)
  • Previous neurosurgical intervention
  • Patients with a progressively fatal disease, or life expectancy £ one year
  • Asthma
  • Severe visual deficit of ophthalmic origin (such as glaucoma, age related macular degeneration, cataract)
  • Fertile women not using adequate contraceptive methods
  • Women who are pregnant or breast feeding
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact: David MALTETE, MD, PhD (0)232888037 ext +33 david.maltete@chu-rouen.fr
France
 
 
NCT01340001
2011/049/HP
2011-A00387-34 ( Other Identifier: ID-RCB )
Yes
Not Provided
Not Provided
Not Provided
University Hospital, Rouen
University Hospital, Rouen
Not Provided
Principal Investigator: Olivier GODEFROY, Md, PhD University Hospital of Amiens
Principal Investigator: Luc DEFEBVRE, MD, PhD University Hospital of Lille
Principal Investigator: HOUETO Jean-Luc, MD, PhD University Hospital of Poitiers
Principal Investigator: Pierre Krystkowiak, MD, PhD University Hospital of Amiens
Principal Investigator: Vincent Delasayette, MD University Hospital of Caen
University Hospital, Rouen
December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP